What is the mechanism of action for Finasteride in the treatment of BPH?

Finasteride is a medication primarily used to treat Benign Prostatic Hyperplasia (BPH) by targeting the hormonal pathways involved in prostate growth. The mechanism of action involves the inhibition of the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT). DHT is a potent androgen that contributes significantly to the enlargement of the prostate.

By decreasing the levels of DHT in the prostate, finasteride effectively reduces the size of the prostate gland and helps alleviate symptoms associated with BPH, such as urinary obstruction and increased urinary frequency. This reduction in DHT also leads to a decrease in overall prostate tissue volume, which can improve urinary flow and reduce symptoms related to the condition.

The other options do not accurately describe the primary mechanism of action of finasteride. While relaxation of bladder muscles and reduction of bladder outlet obstruction are relevant factors in managing BPH symptoms, these effects are not directly achieved through the action of finasteride itself.